ARCHIVES
VOL. 11, ISSUE 2 (2025)
Interferon therapy side effects in patients with chronic liver disease attending GIT babylon center
Authors
Mokhles Turki Abdulkadhim, Muhammed Abdulwahid shuailah, Haider Dhia AlBana
Abstract
This prospective observational study evaluated
the adverse effects of pegylated interferon (PEG-IFN) therapy in 114 patients
with chronic hepatitis B (CHB, n=53) and C (CHC, n=61) at the GIT Babylon
Center from January 2024 to January 2025. Patients received PEG-IFN alfa-2a
(180 µg weekly) and were monitored over three months for side effects,
including flu-like symptoms (91.2%), hematological abnormalities (81.5%), and
neuropsychiatric issues (34.2%). Laboratory changes, such as reduced hemoglobin
(p=0.000) and elevated liver enzymes (p<0.013), were significant, with
adverse effects correlating with treatment duration for some symptoms (e.g.,
arthralgia, p=0.007). Gender and hepatitis type influenced specific side
effects, like anemia in CHC patients. These findings underscore the need for
vigilant monitoring and supportive care to enhance patient outcomes amidst IFN
therapy’s challenges, particularly in resource-limited settings where it
remains relevant.
Download
Pages:67-74
How to cite this article:
Mokhles Turki Abdulkadhim, Muhammed Abdulwahid shuailah, Haider Dhia AlBana "Interferon therapy side effects in patients with chronic liver disease attending GIT babylon center". International Journal of Medical and Health Research, Vol 11, Issue 2, 2025, Pages 67-74
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.